Living meta-analysis and evidence synthesis of therapies for COVID-19

click on circles to display study description...

ACTIV-1 cenicriviroc, 2020 NCT04593940

cenicriviroc (n=-9) vs. placebo (n=-9)

randomized controlled trial   risk of bias NA

Studied treatment

cenicriviroc

Control treatment

placebo

in addition to the standard of care, which may include remdesivir. About 90% received remdesivir, and about 85% received dexamethasone

Patients

COVID-19 severe or critically

Method

46 in the United States and 23 in Latin America

Remark

preliminary results in a press release